Atlas Trials

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

Clinical trial NCT04083833 · COMPLETED

Trial details

NCT number
NCT04083833
Sponsor
Wex Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
TQT Study
Start date
2018-02-07
Primary completion
2018-03-24
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.